Locked content Selvita to build PLN 77 mln R&D center in Kraków

Biotechnology firm Selvita has obtained a building permit for an R&D center in Kraków. The project is estimated to cost PLN 77 million, with PLN 34 million coming from a subsidy from the Ministry of Development. The lab will be operational in H1 2019, the company informed. Selvita plans to inves...

Locked content Biomed-Lublin to acquire investor

Medical preparations and pharmaceuticals producer Biomed-Lublin has signed an agreement with a financial investor regarding preliminary and non-binding conditions of potential capital transaction valued at PLN 200 million. Conducting due diligence and getting approvals from financial committees of t...

Locked content Polish tracheostomy technology to enter US

Polish biotechnological firm Airway Medix has signed a letter of intent with an undisclosed American company in order to introduce its CPR (Cardiopulmonary Resuscitation) products to the American market, the media reported. Airway Medix will not reveal the name of its partner until the deal is not s...

Locked content Selvita to invest in second lab and launch office in San Francisco

WSE-listed biotechnology firm Selvita is going to launch its second laboratory in Poland still this year and is considering opening its subsidiary’s second office in the United States, the ISBnews reported citing Bogusław Sieczkowski, the deputy CEO at the firm. “We have been in talks [r...

Locked content Boruta-Zachem prepars investment worth PLN 100 mln

Chemical company Boruta-Zachem is planning to develop a biorafinery, the value of which may reach PLN 100 million, parkiet.com informed. Boruta-Zachem specializes in the production of dyestuffs and pigments, biosurfactants used in the chemical and cosmetics industries and research and development of...

Locked content Selvita pursues foreign expansion

WSE-listed biotechnology firm Selvita has established a subsidiary, Selvita Ltd.,  in Cambridge, UK, a press release read. It is the company’s second branch based abroad. The first was founded in Boston, US early March. “The UK is a huge market. … We think that our presence here wi...

Locked content Inno-Gene will move to WSE, may be acquired

Poland’s biotechnology company Inno-Gene will submit its prospectus in H2 of 2015 in order to move from the NewConnect alternative market to the Warsaw Stock Exchange main trading floor, ISBnews agency informed. “The company is willing to move its shares from the NewConnect market to the...

Locked content Sołowow invests in biotechnology

Polish tycoon Michał Sołowow invested PLN 12 million in OncoArendi Therapeutics, a company specializing in developing innovative anti-inflammatory and anti-cancer drugs. The sum is to cover R&D work in the next 3 years. “In my opinion, OncoArendi has an exceptional team of outstanding researcher...